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Introduction
The central nervous system (CNS) has long been regarded as an immunologically privileged site due to the persistence of intracerebral tumor allografts and xenografts in immunocompetent hosts capable of rejecting the same tumor grafts in the periphery. 1 Although cytotoxic T-lymphocyte (CTL) responses can be elicited against nonsyngeneic CNS tumor grafts, these responses have not been sufficient to control intracerebral tumor growth. 2 Furthermore, adjuvant immunotherapies otherwise effective in preventing the systemic recurrence of melanoma have failed to prevent relapses in the CNS. 3 The mechanisms limiting immune reactivity in the brain are incompletely understood, but likely include distinctive anatomical features such as the absence of conventional draining lymphatics and the presence of the bloodbrain barrier. 4 Nonetheless, the immunologic privilege of the brain is not absolute. In experimental allergic encephalomyelitis (EAE), peripheral immunization with myelin basic protein (MBP) elicits antigen-specific, CTLmediated CNS demyelination, 5 indicating that specific immunoreactivity in the CNS can result from the appropriate presentation of target antigen and the efficient induction of a systemic effector response. This observation is further strengthened by recent reports that effective anti-CNS tumor immune responses can be generated through the use of cytokine gene-modified tumor cell vaccines. [6] [7] [8] Like many cytokines, interleukin-4 (IL-4) has pleiotropic effects on immune cells of multiple lineages and therefore its potential to induce immunoreactivity to CNS tumors has been explored. IL-4 increases surface major histocompatibility complex class II antigens in B cells, 9 stimulates the growth of both normal helper and cytotoxic T cells, 10 including tumor infiltrating lymphocytes 11 and upregulates the expression of vascular cell adhesion molecule 1 (VCAM-1) on activated endothelia. 12 In addition, the local production of IL-4 from genetically engineered tumor cells induces potent protective 13, 14 and therapeutic immunity 15, 16 in non-CNS animal models. IL-4, in combination with granulocyte-macrophage colonystimulating factors (GM-CSF), also promotes the acquisition of a dendritic cell phenotype and function in mouse bone marrow 17 and human cord blood CD34 + cell 18 cultures. The herpes simplex virus-thymidine kinase (HSVtk) gene, in combination with the antiviral drug ganciclovir (GCV), has been used in both preclinical models 19, 20 and clinical trials for the treatment of CNS tumors. 21 As a mechanism for enhancing the safety of vaccine administration, we have introduced the HSVtk gene into a retroviral vector encoding the murine IL-4 and neomycin phosphotransferase (neo R ) genes using an equine encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES) sequence to promote efficient gene expression. Transduction of the HSVtk gene confers sensitivity of mammalian cells to treatment with the antiviral agent ganciclovir (GCV) by specifically phosphorylating GCV and resulting in the subsequent inhibition of DNA synthesis. 22 By incorporating the HSVtk gene into glioma vaccines and subsequently treating vaccinated patients with GCV, we hope to eliminate the small potential for local tumor growth at the site of vaccination and to enhance the delivery of tumor antigens to antigenpresenting cells. Antitumor immunity is, in fact, reported to be induced following HSVtk-mediated killing of experimental brain tumors in vivo. 23 Thus, another potential advantage of introducing the HSVtk gene may be to induce antitumor immunity more effectively than with the use of the IL-4 gene alone. This hypothesis is further supported by the effectiveness of combination cytokine and HSVtk gene therapy in a liver metastasis model 24 and in direct gene transfer to intracranial tumor models. 25 In this report, we describe the use of genetically modified, nonirradiated 9L tumor vaccines, expressing either the murine IL-4 gene, the HSVtk gene, or both genes, to induce protective and therapeutic immunity against parental 9L tumors. We also compare the efficacy of nonirradiated IL-4 transduced tumor cell vaccines with irradiated whole cell vaccines in the treatment of intracranial (i.c.) 9L tumors. The mechanism underlying the induction of effective host antitumor immunity was examined in part by evaluating the in vitro IFN-␥ expression from splenocytes from immunized animals.
Results

In vitro characterization of transfected cells
The schema of constructs for retroviral vectors encoding the cDNAs for mIL-4, HSVtk and neo R are shown in Figure 1. Single gene, dual genes (DFG), or triple genes (TFG) were inserted into the retroviral backbone (MFG). There were no significant differences between wild-type 9L and 9L transfectants, including the 9L-neo, 9L-Tk, 9L- To evaluate the sensitivity of the HSVtk gene-transfected cell lines to GCV, aliquots of cells were incubated with various concentrations of GCV for 5 days. As shown in Figure 2 , the percentage cell survival of 9L-Tk and 9L-IL4-Tk, determined by comparison with transfectants cultured without GCV, was reduced with low concentrations of GCV (10 g/ml) to 0% and 3.3%, respectively. 9L-Tk cells were found to be more sensitive to the cytotoxic effect of GCV than 9L-IL4-Tk. High doses of GCV treatment had a mild inhibitory effect on 9L-neo cell growth.
Growth of subcutaneous 9L transfected tumors
To evaluate whether constitutive IL-4 production affects tumor formation in vivo, rats were injected s.c. with 2 × 10 6 9L or 9L transfectants. As shown in Figure 3a , all animals receiving 9L or 9L-neo cells subcutaneously developed tumors that grew progressively without a statistically significant difference (P = 0.316 on day 21) and were killed on day 21 because of progressive tumor growth. 9L-Tk cells grew progressively in all animals but the growth rate was reduced when compared with that of 9L (P = 0.026) and 9L-neo (P = 0.037) on day 21. In contrast, animals injected with 2 × 10 6 9L-IL4 or 9L-IL4-Tk cells initially formed a small tumor mass but these animals completely rejected tumors by day 30. In the next series of experiments, animals injected with 2 × 10 6 9L-neo, 9L-IL4, 9L-Tk or 9L-IL4-Tk cells were treated with 
Figure 3 Subcutaneous tumor growth in Fischer rats is inhibited by IL-4 and HSVtk expression. (a) Following the s.c. injection of two million cells on day 0, serial measurements were made and expressed as mean tumor area (n = 4 per group). (b) The same number of cells were injected, then GCV (15 mg/kg × 2 per day) was administered i.p. from day 7 to day 13 (n = 4 per group). Closed diamonds, wild-type 9L; closed squares, 9L-neo; closed triangles, 9L-Tk; closed circles, 9L-IL4; asterisks, 9L-IL4-Tk.
intraperitoneal injections of GCV (15 mg/kg twice a day) from days 7 to 13. As shown in Figure 3b , tumors of 9L-Tk and 9L-IL4-Tk were completely eliminated by day 14 following GCV administration. None of these animals developed tumor recurrence during a 100-day observation period, suggesting that HSVtk-transduced tumor cells were completely eliminated. In contrast, 9L-neo or 9L-IL4 tumor growth was not affected by this dose of GCV. Irradiated 9L-neo or 9L-IL4 cells did not form any detectable tumors following s.c. injection.
Protection of intracranial tumor growth by IL-4 or IL4-Tk tumor vaccines
We next assessed the efficacy of IL-4 and HSVtk tumor vaccines for preventing the establishment of i.c. tumors.
Rats were immunized by injecting 2 × 10 6 9L-transfectants s.c. on day −28. Control animals received HBSS or irradiated 9L-neo s.c. on day −28. GCV (15 mg/kg × 2 per day) was administered to the animals from day −21 to day −15 and animals were then challenged i.c. on day 0 with 1 × 10 5 9L cells. As shown in Figure 4 , no animals either in the HBSS or irradiated 9L-neo immunized group survived for more than 23 days (median survival 11 and 13 days, respectively). Large tumors were observed in the brains of these animals upon necropsy (data not shown). In contrast, survival of the 9L-Tk-treated animals was prolonged when compared with that of control animals (P = 0.0001), with four of eight 9L-Tk-treated animals surviving for more than 100 days. Furthermore, all animals immunized with nonirradiated 9L-IL4 or 9L-IL4-Tk survived longer than 100 days (P Ͻ 0.0001 compared with the HBSS group, P = 0.0250 with the 9L-Tk group). The intracranial challenge dose was increased to 1 × 10 6 cells in nonirradiated 9L-IL4 (n = 4) and 9L-IL4-Tk (n = 4) immunized animals, and all animals survived for more than 120 days (data not shown). To characterize the tumor histologically, rats immunized with 9L-transfectants on day −28 and inoculated i. 
Histologic examinations revealed a prominent infiltration of mononuclear cells and minimal residual tumor cells in the brains of 9L-IL4-Tk immunized animals (A). Similar findings were observed in the brains of 9L-IL4 immunized animals (not shown). Modest infiltration of mononuclear cells in residual tumor cell nests was observed in the brains of 9L-Tk immunized animals (B). In contrast, large tumors without a significant leukocyte infiltration were identified in the brains of control irradiated 9L-neo immunized animals (C). Original magnification ×200.
nests was observed in the brains of 9L-Tk immunized animals ( Figure 5B ). In contrast, large intracranial tumors, without significant leukocyte infiltration, were observed in the brains of control irradiated 9L-neo immunized animals ( Figure 5C ).
Effective therapy of intracranial 9L tumors using IL4-Tk vaccines
The therapeutic potential of 9L-Tk, 9L-IL4, and 9L-IL4-Tk tumor vaccines was assessed in Fischer 344 rats with established intracranial 9L tumors. In these experiments, animals receiving nonirradiated 9L-transfectants were treated with a single s.c. injection of 2 × 10 6 cells 3 days after the intracranial injection of 1 × 10 4 wild-type 9L cells. Animals treated with irradiated 9L-neo, irradiated 9L-IL4 or control HBSS vaccines received s.c. injections of 2 × 10 6 cells on days 3, 7, 10 and 14 after intracranial 9L cell inoculation. As shown in Figure 6 , survival of animals in the nonirradiated 9L-IL4-Tk and 9L-IL4 treatment groups was significantly prolonged when compared with that of HBSS-treated animals. For 9L-IL4-Tk-treated animals, two of eight (25%, P = 0.0099 compared with the HBSS treatment group) survived for more than 100 days when GCV was administered from day 7 to 13 and six of 14 (42.9%, P = 0.0002) achieved a long-term survival (у100 days) when GCV was administered from days 14-20. Modifying the schedule of GCV administration (days 7-13 or 14-20) in animals receiving the 9L-IL4-Tk vaccine did not significantly alter the long-term survival rate (P Ͼ 0.5). In the nonirradiated 9L-IL4 treatment group, four of 15 animals (26.7%, P = 0.008) survived long term. Animals treated with 9L-IL4-Tk vaccines and GCV from days 14-20 showed a trend toward increased survival when compared with those receiving nonirradiated 9L-IL4 vaccines, however, this difference did not achieve statistical significance (P Ͼ 0.5). In contrast, none of the HBSS, irradiated 9L-neo, irradiated 9L-IL4 or nonirradiated 9L-Tk-treated animals survived beyond 33 days, and median survival was 19, 18, 23 and 20 days, respectively.
Tumor-specific IFN-␥ production by splenocytes induced by IL-4 or HSV-TK and GCV To evaluate the potential induction of antitumor cellular immunity by vaccination with 9L transfectants, splenocytes from immunized animals were harvested, cultured in the presence of stimulator cells and low-dose human IL-2, and assayed for the production of IFN-␥. As shown in Figure 7 , IFN-␥ production was up-regulated in splenocytes harvested from 9L-Tk, nonirradiated 9L-IL4 and 9L-IL4-Tk immunized animals following stimulation with irradiated wild-type 9L cells. IFN-␥ production was comparable in 9L-Tk, nonirradiated 9L-IL4 and 9L-IL4-Tk immunized rats and determined to be 2714, 2232 and 2283 pg per one million splenocytes for 5 days, respectively. In contrast, splenocytes from the HBSS or irradiated 9L-neo treated animals produced only 489 and 791 pg of IFN-␥, respectively. The data shown in Figure  7 is representative of three independent experiments. In one of three experiments, splenocyte IFN-␥ production was higher in the nonirradiated 9L-IL4 and 9L-IL-4-Tk immunized groups than the 9L-Tk group (data not shown). The up-regulated IFN-␥ production is 9L specific since splenocytes from 9L-Tk, nonirradiated 9L-IL4 or 9L-IL4-Tk animals produce only background levels of IFN-␥ when stimulated with syngeneic MADB106 cells.
Figure 6 Therapeutic immunity induced by 9L-IL4 or 9L-IL4-Tk vaccines. Survival of rats with established (day 3) intracranial 9L tumors was significantly prolonged by treatment with nonirradiated IL-4-expressing tumor cell vaccines. Animals inoculated i.c. with 1 × 10 4 9L cells on day 0 were treated with s.c. injections of 2 × 10 6 9L-transfectants or HBSS on day 3. The data shown are cumulative survival results for animals in three independent experiments. Number of animals (n), median survival (days), range and significance compared with HBSS-immunized animals for each group are as follows: closed circles, HBSS (n = 11): 19 days, 17 to 33 days; closed triangles, irradiated 9L-neo (n = 18): 18 days, 16-26 days, NS (NS, not significant); open triangles, nonirradiated 9L-Tk (n = 8): 20 days, 17-32 days, NS; open circles, nonirradiated 9L-IL4 (n = 15): 26 days, 19-Ͼ100 days, p = 0.008; closed diamonds, irradiated 9L-IL4 (n = 8): 23 days, 20 to 28 days, NS; open squares, nonirradiated 9L-IL4-Tk (GCV administered day 7-13, n = 8): 26 days, 21-Ͼ100 days, P = 0.0099; closed squares, nonirradiated 9L-IL4-Tk (GCV administered day 14-20, n = 14): 26 days, 20-Ͼ100 days, P = 0.0002. No statistically significant difference was observed in the survival of the nonirradiated 9L-IL4 treatment group and the 9L-IL4-Tk treatment groups, or in the survival of the 9L-IL4-Tk treatment groups receiving alternate GCV administration schedules.
Discussion
The data reported in this paper demonstrate that potent immunity against intracranial 9L tumors is induced in syngeneic Fischer 344 rats by peripheral immunization with mIL-4 or mIL-4 plus HSVtk-transduced nonirradiated 9L cells. Although immunological tolerance is a well described and distinguishing biological feature of the brain, active immunization with cytokine geneengineered tumor cells, as also shown by others, can break nominal CNS tolerance. [6] [7] [8] In our treatment model, vaccination with nonirradiated 9L-IL4 tumor cells was found to be significantly more effective in increasing survival in Fischer rats with established intracranial tumors when compared with repetitive vaccination with irradiated IL-4 expressing tumor cells (P = 0.0111). This observation is consistent with other investigators' findings [26] [27] [28] and provides a rationale for the clinical use of nonirradiated tumor vaccines.
Figure 7 Specific IFN-␥ expression by splenocytes from immunized rats. The specific production of IFN-␥ by splenocytes harvested from IL-4 or HSVtk-expressing tumor-immunized rats following in vitro stimulation by wild-type 9L was measured. Splenocytes were harvested on day 0 from animals immunized 28 days earlier with control HBSS, irradiated 9L-neo, 9L-Tk, 9L-IL4 or 9L-IL4-Tk vaccines and treated with GCV from days
In clinical trials of glioma vaccines, nonimmune mediated inhibition of local tumor vaccine growth will enhance the safety of vaccine administration, and therefore we have chosen to incorporate the HSVtk gene into our retroviral vector constructs. The effective expression of each gene in the polycistronic transcripts encoded by the viral vectors is achieved by inserting IRES cassettes between sequential genes. 29, 30 As expected, 9L-IL4-Tk and 9L-IL4 cell lines produced equivalent amount of IL-4 in vitro, while 9L-IL4-Tk cells showed slightly reduced GCV sensitivity when compared with 9L-Tk cells (Figure 2 ). This variation in GCV sensitivity may reflect the proximity of the HSVtk gene to the 5Ј LTR in the DFG-Tk-neo vectors relative to the TFG-mIL4-neo-Tk vectors. These in vitro data support the feasibility of the use of the TFG construct in human clinical trials. In vivo, syngeneic Fischer rats rejected both 9L-IL4 and 9L-IL4-Tk tumor vaccines by day 30 (Figure 3a) . Nonetheless, the potential for local tumor growth in clinical trials of autologous, cytokine-modified nonirradiated tumor vaccines must be acknowledged and may be affected by factors such as IL-4 production 14 and host immunocompetence. Low-dose GCV administration produced rapid elimination of 9L-Tk and 9L-IL4-Tk tumors in vivo but did not affect 9L-neo and nonirradiated 9L-IL4 tumor growth (Figure 3) , suggesting that in vivo GCV treatment had no significant impact on non-TK expressing cell growth or host immunity. Conversely, 50% of animals immunized with 9L-Tk cells followed by in vivo GCV treatment rejected a subsequent i.c. tumor challenge (Figure 4 ). These data suggest that GCV-mediated elimination of 9L-Tk tumors afforded some level of protective antitumor immunity, possibly through the induction of tumor cell death and the subsequent recruitment of host immune cells. While some inhibition of s.c. tumor growth was observed in 9L-Tk tumors relative to 9L-neo tumors (Figure 3a) , 9L-Tk tumor growth was progressive and lethal in the absence of GCV treatment.
In comparison with HBSS treatment, vaccination with irradiated 9L-neo cells conferred no increase in protective immunity for animals challenged after vaccination with i.c. 9L tumor and no increase in survival for animals with previously established i.c. tumor. These data indicate that the 9L cell line is only weakly immunogenic in the Fischer rats. Significant immunity against wild-type 9L cells could be generated by immunization with 9L-Tk tumor cells only following GCV administration. Although 50% of animals were protected from a subsequent i.c. tumor challenge by 9L-Tk immunization, by comparison, immunity for animals vaccinated with nonirradiated 9L-IL4 or 9L-IL4-Tk was complete. These observations suggest that the antitumor immunity generated by HSVtk expression and GCV administration alone has limited clinical relevance.
We are aware that there are fundamental differences between rodent models and human disease, particularly in terms of aggressiveness of growth of rodent tumors. The acute nature of the disease in rats requires that either a small innoculum of tumor cells be used to provide an opportunity for immunizing rats with established tumors (ie use of 1 × 10 4 cells intracranially) and/or that early establishment models be used (ie day 3 established tumors). The success in evoking a protective response in rodents further supports the idea of using a similar approach in humans as the progression of human disease provides a longer period of time to induce a specific response against established tumors. A more compelling question is whether strategies can be developed for immunization in the periphery which will lead to protective responses to intracranial tumors. In addressing this question, in these models, we have carried out histological examination of intracranial tumors demonstrating that host immune cells could infiltrate the CNS and eliminate intracerebral tumor if animals were previously immunized with IL-4-expressing tumor cells ( Figure 5) . A reduced infiltration of mononuclear cells within residual tumor nests was observed in the brains of the 9L-Tktreated animals relative to 9L-IL4-or 9L-IL4-Tk-treated animals, providing further evidence that the induction of an immune response by 9L-Tk plus GCV treatment was not as effective as that of the IL-4 tumor vaccine. IL-4 may, in fact, act synergistically with HSVtk and GCV, since treatment with a vaccine simultaneously expressing the HSVtk gene and the mIL-4 gene produced long-term survival rates that were slightly higher (P Ͼ 0.5) than that observed in animals treated with the nonirradiated 9L-IL4 vaccine alone. Nonetheless, the incorporation of the HSVtk gene followed by GCV treatment in combination with IL-4 in this vaccination strategy would serve primarily as a safety factor for patients, while enhancing the induction of antitumor immunity would be a secondary objective.
The mechanism for immune induction by IL-4 transduced tumor vaccines or tumor vaccines transduced with HSVtk followed by GCV treatment was analyzed in part by determining cytokine (IFN-␥) production from splenocytes of animals vaccinated with the 9L transfectants. Unexpectedly high levels of IFN-␥ production from splenocytes of animals treated with 9L-Tk after in vitro stimulation with 9L cells provided strong evidence of a cellular immune response induced by HSVtk plus GCV. Although we have not seen significant necrotic tumor cell lysis in our in vitro CTL assays using nonirradiated 9L-IL4 or 9L-Tk immunized splenocytes as effector cells and 9L cells as targets (unpublished observation), the limited protective immunity induced by 9L-Tk-neo and GCV treatment in vivo may be effected by other mechanisms such as the induction of apoptotic death as has been observed in preliminary experiments. IFN-␥ production from 9L-Tk immunized splenocytes was unexpectedly equivalent to that from nonirradiated 9L-IL4 or 9L-IL4-Tk immunized splenocytes. The increased survival rate in animals immunized with IL-4 producing cells cannot only be attributed to enhanced IFN-␥ production and clearly requires other factors which are presently under investigation. We have not been able to detect IL-4 production by splenocytes from immunized rats to date, although other investigators have demonstrated the induction of a T-helper cell type 2 response following vaccination with IL-4 expressing tumor vaccines.
14 Furthermore, intact T cell-mediated immunity, for instance, is thought to be necessary for the induction of an effective antitumor immune response, since in athymic rats, 9L-IL4 tumors injected s.c. grew progressively as did control 9L and 9L-neo tumors (data not shown). This is consistent with reports by others in which the induction of systemic immunity to the parental tumor by immunization with IL-4-transfected tumors was T cell-dependent. 14, 15 Interestingly, it has recently been reported that IL-4-transduced cancer cells increased the influx of dendritic cells to the tumor site relative to other cytokines. 31 Taken together, these findings suggest that IL-4-transduced tumors can be used to induce effective immune response to parental tumors and confirm the feasibility of this strategy in clinical trials of CNS tumors.
Materials and methods
Tumor cells and brain tumor model Rat 9L gliosarcoma cells and MADB106 mammary adenocarcinoma cells derived from Fischer 344 rats were maintained in minimum essential medium or RPMI 1640 supplemented with 10% fetal bovine serum, 100 units/ml penicillin G and 100 units/ml of streptomycin sulfate, respectively. Brain tumors were established in male Fischer 344 rats which were housed and handled in accordance with the guidelines for animal care established by the University of Pittsburgh Animal Care and Use Committee. Using a 10-l Hamilton syringe, 1 × 10 4 (treatment model) or 1 × 10 5 (protection model) 9L cells suspended in 5 l of HBSS were stereotactically injected 2 mm anterior to Bregma, 2.2 mm to the right of the sagittal suture and 4 mm below the surface of the skull of ane-sthetized rats using a Kopf stereotactic frame (Kopf Instruments, Tujunga, CA, USA).
Recombinant retroviral vectors and infection
The cDNAs of murine IL-4, HSVtk were subcloned into NcoI and BamHI sites of MFG 32 ( Figure 1 ). Modified MFG-based retroviral vectors termed DFG-mIL4-Neo, DFG-Tk-Neo and TFG-mIL4-Neo-Tk were constructed by connecting cDNA fragments with one or two intervening internal ribosomal entry site (IRES) fragments of encephalomyocarditis virus (EMCV) obtained from the pCITE plasmid (Novagen, Madison, WI, USA). DFG and TFG vectors coordinately express two or three independent genes from a single transcript driven by the 5Ј long terminal repeat (LTR). The MFG-Neo retroviral vector carrying only neo R was used as a negative control. Retroviral supernatant was generated by transfecting vector plasmids into the CRIP packaging line 33 or BOSC23 packaging cell line 34 (generously provided by Dr Pear, Stanford University, CA, USA and Dr Baltimore, The California Institute of Technology, CA, USA). Target 9L cells were infected by exposure to supernatant for 4 h in the presence of 8 g/ml polybrene, then continuously selected in 1 mg/ml of G418. Selected colonies were collected and expanded, maintained in culture, and regularly determined to be free of mycoplasma contamination using a mycoplasma detection kit (Boehringer Mannheim, Indianapolis, IN, USA).
IL-4 assay IL-4 production by transfected tumor cells was measured in an ELISA using antibodies obtained from PharMingen (San Diego, CA, USA) and expressed as nanograms per 10 6 cells per 48 h.
In vitro tumoricidal effects of GCV on HSVtk transduced tumor cells Aliquots of 1 × 10 4 cells were inoculated into each well of 24-well plates (Falcon 3047; Becton Dickinson, Lincoln Park, NJ, USA) with 500 l of medium. Twenty-four hours later, graded concentrations of GCV (Cytovene-IV; Hoffmann-La Roche, Nutley, NJ, USA) were added to each well. Numbers of living cells were counted 120 h thereafter, using the trypan blue dye exclusion method. Each plot in the graph represents the average of triplicates.
Immunization with subcutaneous injection of genemodified tumor cells Subcutaneous tumor growth and tumor immunizations were performed by injecting 0.5 ml of HBSS containing exponentially growing 2 × 10 6 gene-modified or control wild-type 9L cells s.c. in the right flank of syngeneic Fischer 344 rats. 9L-neo cells and 9L-IL4 cells used as irradiated tumor vaccines were irradiated with 40 Gy using Gammacell 1000 Elite cell irradiator (MDS Nordion, Kanata, Ontario, Canada) before injection. Tumor size was calculated using calipers by multiplying the long axis of the tumor and the greatest perpendicular axis. In the protection model, 2 × 10 6 irradiated or nonirradiated cells were injected s.c. 28 days before the i.c. tumor challenge. In the treatment models, animals with day 3 established i.c. tumors were given 2 × 10 6 vaccine cells s.c., and for the groups treated with irradiated cells, injections were repeated on days 7, 10 and 14 after i.c. tumor inoculation. For animals receiving HSVtk gene transfected cells, 15 mg/kg GCV was administered twice a day intraperitoneally from either day 7 to day 13 or day 14 to day 20 after s.c. tumor injection.
Histology
A subset of rats that were immunized s.c. with 2 × 10 6 9L-IL4-TK, 9L-IL4, 9L-TK or irradiated 9L-neo on day −28 and received 1 × 10 5 9L cells i.c. on day 0 were killed on day 7. Brains were fixed in a 10% formalin solution, dehydrated and embedded in paraffin. Sections (5 m) were made and stained with hematoxylin and eosin.
Cytokine production by splenocytes Splenocytes were collected from animals immunized 28 days earlier with irradiated 9L-neo, 9L-Tk, nonirradiated 9L-IL4 or 9L-IL4-Tk. Aliquots of 1 × 10 6 splenocytes were cultured with 3.3 × 10 4 irradiated 9L cells in the presence of 50 IU/ml of recombinant human IL-2 for 5 days. Aliquots of supernatant from each culture were added to the each well of a 96-well plate precoated with either antirat IFN-␥ or anti-rat IL-4 supplied with cytokine ELISA kits (PharMingen).
Statistical analysis
Survival estimates and median survival times were determined using the method of Kaplan and Meier. Survival data were compared using Wilcoxon's log rank test. Growth of s.c. tumors was evaluated by t test for two samples with unequal variances. Statistical significance was determined at the Ͻ0.05 level.
